“Castle started their due diligence several months ago? And it resulted in their believing that they could raise $45million on behalf of this Expert Market Company?”
Have you seen what Saniona got in a deal with Acadia for a similar selective gabakine? KRM-ll-81 has a much more extensive and robust preclinical profile.